Article Sidebar

PDF
Date Published: 28/06/2023
Abstract Views: 134
Views PDF: 85
DOI: https://doi.org/10.56535/jmpm.v48i5.356
Issue
Vol. 48 No. 5 (2023): JOURNAL OF MILITARY PHARMACO-MEDICINE 5-2023
Section
Articles
How to Cite
Nguyen, D. U., Le, V. N., Nguyen, H. T., Nguyen, T. C., & Ho, H. T. (2023). STUDY ON CHANGES IN SERUM HBV RNA LEVELS IN PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH TENOFOVIR DISOPROXIL FUMARATE. Journal of Military Pharmaco-medicine, 48(5), 124-136. https://doi.org/10.56535/jmpm.v48i5.356

STUDY ON CHANGES IN SERUM HBV RNA LEVELS IN PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH TENOFOVIR DISOPROXIL FUMARATE

Nguyen Dinh Ung1, , Le Van Nam2, Nguyen Hong Thang2, Nguyen Trong Chinh2, Ho Huu Tho1
1 Vietnam Military Medical University
2 Military Hospital 103, Vietnam Military Medical University

Main Article Content

Abstract

Objectives: To determine the changes in serum HBV RNA levels in treatment-naïve chronic hepatitis B (CHB) patients who were treated with Tenofovir Disoproxil Fumarate (TDF). Methods: 77 treatment-naïve CHB patients were treated with long-term TDF monotherapy at the Department of Infectious Diseases, Military Hospital 103, Vietnam Military Medical University from 2017 to 2020. Samples were collected at several time points: At the baseline, after 3, 6, 9, and 12 months of TDF treatment. Serum HBV DNA and HBV RNA levels were quantified by the Real Time RT-PCR method. Statistical analyses were performed with Medcalc 20.019. Results: Serum HBV RNA levels tended to decrease during the TDF treatment in a biphasic pattern. In the first phase, from baseline to 3 months of treatment, HBV RNA levels decreased rapidly (the median slope of the decrease was 0.38 log copies/mL/month). In the second phase, from 3 - 12 months of treatment, serum HBV RNA levels decreased more slowly than in the first phase (the median slope of the decrease was 0.09 log copies/mL/month; p < 0.05). Serum HBV RNA levels decreased more slowly than serum HBV DNA levels in the first phase, but there was no significant difference in the second phase (p > 0.05). Conclusion: Serum HBV RNA levels decreased in a biphasic pattern with a different slope during TDF treatment. Serum HBV RNA levels decreased more slowly than HBV DNA and may complement this marker in the assessment of treatment outcomes and prognosis for chronic hepatitis B.

Article Details

Keywords

Chronic Hepatitis B (CHB), HBV pgRNA

References

1. Yun-Fan Liaw and Chia-Ming Chu. "Hepatitis B virus infection". The Lancet. 2009; 373(9663):582-592.
2. Brittney S Sheena et al. Global, regional, and national burden of hepatitis B, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. The Lancet Gastroenterology & Hepatology. 2022; 7(9):796-829.
3. Catharina J Alberts et al. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: A systematic review. The Lancet Gastroenterology & Hepatology. 2022.
4. Hariklia Kranidioti, Spilios Manolakopoulos, and Salim I Khakoo. Outcome after discontinuation of nucleot (s) ide analogues in chronic hepatitis B: Relapse rate and associated factors. Annals of Gastroenterology: Quarterly publication of the Hellenic Society of Gastroenterology. 2015; 28(2):173.
5. Florian van Bömmel et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology. 2015; 61(1): 66-76.
6. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. Journal of Hepatology. 2012; 57(1): 167-185.
7. Jie Wang et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. Journal of Hepatology. 2016; 65(4):700-710.
8. Bộ Y tế. Hướng dẫn chẩn đoán và điều trị bệnh viêm gan vi rút B. 2019.
9. Shi Liu et al. Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg‐positive chronic hepatitis B treated with nucleos (t) ide analogues. Alimentary Pharmacology & Therapeutics. 2020; 52(4):692-700.
10. M-C Tsai et al. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: Real world experience. Clinical Microbiology and Infection. 2016; 22(1):95. e1-95. e7.
11. Louis Jansen et al. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos (t) ide analogues. The Journal of Infectious Diseases. 2016; 213(2):224-232.
12. I-Chin Wu et al. Clinical implications of serum hepatitis B virus pregenomic RNA kinetics in chronic hepatitis B patients receiving antiviral treatment and those achieving HBsAg loss. Microorganisms. 2021; 9(6):1146.